 | Up a level |
Thürlimann, B.; Beretta, K.; Bacchi, M.; Castiglione-Gertsch, M.; Goldhirsch, A.; Jungi, W. F.; Cavalli, F.; Senn, H.-J.; Fey, M.; Löhnert, T. (1996). First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Annals of oncology, 7(5), pp. 471-479. Oxford University Press 10.1093/oxfordjournals.annonc.a010635
